PTCT PTC Therapeutics Inc.

37.41
+0.47  (+1%)
Previous Close 36.94
Open 36.97
Price To Book 6.22
Market Cap 2184807522
Shares 58,401,698
Volume 608,565
Short Ratio
Av. Daily Volume 920,202

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 3 data due 2019.
RG7916 - SUNFISH
Spinal Muscular Atrophy (SMA)
Received a Refusal to File letter February 23 2016. Appeal rejected October 17, 2016. Decision made to resubmit NDA during 1Q 2017 under protest. Further CRL October 25, 2017. New trial initiated 4Q 2018.
Translarna
Duchenne muscular dystrophy caused by nonsense mutations (nmDMD)
FDA Approval announced October 5, 2018,
Inotersen (IONIS-TTRRx)
NEURO-TTR - familial amyloid polyneuropathy (FAP).
Phase 3 data released March 2, 2017 - endpoints not met. Development to be discontinued.
Translarna
Nonsense mutation cystic fibrosis
Noted March 15, 2018 that trial has transitioned into pivotal phase. Updated positive Phase 1 data released June 16, 2018.
RG7916 - FIREFISH
Spinal Muscular Atrophy (SMA) Type 1
BLA filing due late-2019.
GT-AADC
AADC deficiency

Latest News

  1. Edited Transcript of PTCT earnings conference call or presentation 28-Feb-19 9:30pm GMT
  2. Is PTC Therapeutics, Inc.’s (NASDAQ:PTCT) Balance Sheet Strong Enough To Weather A Storm?
  3. Research Report Identifies E*TRADE Financial, Kennedy-Wilson, Alteryx, PTC Therapeutics, Ocean Power Technologies, and NuVasive with Renewed Outlook — Fundamental Analysis, Calculating Forward Movement
  4. PTC Therapeutics to Participate at Upcoming Investor Conferences
  5. PTC to Expand Product Portfolio in Latin America with WAYLIVRA™
  6. PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
  7. PTC Therapeutics Inc (PTCT) Q4 2018 Earnings Conference Call Transcript
  8. PTC Therapeutics Reports Fourth Quarter and Full Year 2018 Financial Results and Provides a Corporate Update
  9. PTC Therapeutics Announces Partial Exercise of Underwriter's Option to Purchase Additional Shares
  10. Sell-Side Picks Top Gene Therapy Takeout Candidates Following Spark Therapeutics Deal
  11. Earnings Preview: PTC Therapeutics (PTCT) Q4 Earnings Expected to Decline
  12. PTC Therapeutics to Host Conference Call to Discuss Fourth Quarter and Year End 2018 Financial Results
  13. PTC Therapeutics Launches Fifth Annual STRIVE Grant Award Program for Duchenne Muscular Dystrophy
  14. Top Insider Buys Highlight for the Week of Feb. 1
  15. PTC Therapeutics Launches New Program to Support Research Projects in Rare, Genetic Disorders
  16. What Kind Of Shareholders Own PTC Therapeutics, Inc. (NASDAQ:PTCT)?
  17. Report: Exploring Fundamental Drivers Behind Realty Income, United Therapeutics, NxStage Medical, PTC Therapeutics, AVEO Pharmaceuticals, and Owens & Minor — New Horizons, Emerging Trends, and Upcoming Developments
  18. Why Capital One Financial, PTC Therapeutics, and Quotient Technology Slumped Today
  19. Here's Why PTC Therapeutics Fell as Much as 11.7% Today